Axsome Therapeutics (AXSM) Misses Q2 EPS by 5c

Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($1.06), $0.05 worse than the analyst estimate of ($1.01). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $6.92 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Keurig Dr Pepper coffee chief to depart ahead of planned split
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight